FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products - Foley & Lardner LLP
FDA issued a clarification on compounding policies for GLP-1 products, impacting outsourcing facilities (503B) and potentially other compounders. The guidance addresses when compounding of these drugs is permissible during shortages and outlines compliance expectations under cGMP.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Compounding outsourcing facilities (503B) and pharmacies compounding GLP-1 products should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate; FDA may take enforcement action for non-compliant compounding.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA clarified that compounding of GLP-1 products is only allowed when the drug is on the FDA shortage list and must comply with cGMP and other requirements. The agency also reiterated that large-scale compounding of essentially copies of FDA-approved drugs is not permitted.
Who it affects
Compounding outsourcing facilities (503B) and pharmacies compounding GLP-1 products
What you must do
Review current compounding practices for GLP-1 products to ensure compliance with the clarified policy, including verifying shortage status and adhering to cGMP.
Deadline
Immediate; FDA may take enforcement action for non-compliant compounding.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness